Chapter 6 Mutations in Melanocortin-4 Receptor and Human Obesity

Progress in Molecular Biology and Translational Science

Volumn 88, Issue C, 2009, Pages 173-204

  Tao, Ya Xiong ^a  

^a AUBURN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEPTIN; MELANOCORTIN 4 RECEPTOR;

CHEMISTRY; CLASSIFICATION; ENERGY METABOLISM; GENETICS; HUMAN; METABOLISM; MUTATION; OBESITY; PHENOTYPE; REVIEW;

ENERGY METABOLISM; HUMANS; LEPTIN; MUTATION; OBESITY; PHENOTYPE; RECEPTOR, MELANOCORTIN, TYPE 4;

EID: 77955357085     PISSN: 18771173     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1877-1173(09)88006-X     Document Type: Review

References (186)

1. Bessesen D.H. Update on obesity. J Clin Endocrinol Metab 93 (2008) 2027-2034
2. Adams K.F., Schatzkin A., Harris T.B., Kipnis V., Mouw T., Ballard-Barbash R., et al. Overweight, obesity, and mortality in a large prospective cohort of persons 50 to 71 years old. N Engl J Med 355 (2006) 763-778
3. Allison D.B., Fontaine K.R., Manson J.E., Stevens J., and VanItallie T.B. Annual deaths attributable to obesity in the United States. JAMA 282 (1999) 1530-1538
4. Bibbins-Domingo K., Coxson P., Pletcher M.J., Lightwood J., and Goldman L. Adolescent overweight and future adult coronary heart disease. N Engl J Med 357 (2007) 2371-2379
5. Baker J.L., Olsen L.W., and Sorensen T.I. Childhood body-mass index and the risk of coronary heart disease in adulthood. N Engl J Med 357 (2007) 2329-2337
6. Christakis N.A., and Fowler J.H. The spread of obesity in a large social network over 32 years. N Engl J Med 357 (2007) 370-379
7. O'Rahilly S., Farooqi I.S., Yeo G.S., and Challis B.G. Minireview: human obesity-lessons from monogenic disorders. Endocrinology 144 (2003) 3757-3764
8. Smith A.I., and Funder J.W. Proopiomelanocortin processing in the pituitary, central nervous system, and peripheral tissues. Endocr Rev 9 (1988) 159-179
9. Ollmann M.M., Wilson B.D., Yang Y.K., Kerns J.A., Chen Y., Gantz I., et al. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 278 (1997) 135-138
10. Nijenhuis W.A., Oosterom J., and Adan R.A. AgRP(83-132) acts as an inverse agonist on the human melanocortin-4 receptor. Mol Endocrinol 15 (2001) 164-171
11. Haskell-Luevano C., and Monck E.K. Agouti-related protein functions as an inverse agonist at a constitutively active brain melanocortin-4 receptor. Regul Pept 99 (2001) 1-7
12. Mountjoy K.G., Robbins L.S., Mortrud M.T., and Cone R.D. The cloning of a family of genes that encode the melanocortin receptors. Science 257 (1992) 1248-1251
13. Roselli-Rehfuss L., Mountjoy K.G., Robbins L.S., Mortrud M.T., Low M.J., Tatro J.B., et al. Identification of a receptor for γ melanotropin and other proopiomelanocortin peptides in the hypothalamus and limbic system. Proc Natl Acad Sci USA 90 (1993) 8856-8860
14. Gantz I., Konda Y., Tashiro T., Shimoto Y., Miwa H., Munzert G., et al. Molecular cloning of a novel melanocortin receptor. J Biol Chem 268 (1993) 8246-8250
15. Gantz I., Miwa H., Konda Y., Shimoto Y., Tashiro T., Watson S.J., et al. Molecular cloning, expression, and gene localization of a fourth melanocortin receptor. J Biol Chem 268 (1993) 15174-15179
16. Gantz I., Shimoto Y., Konda Y., Miwa H., Dickinson C.J., and Yamada T. Molecular cloning, expression, and characterization of a fifth melanocortin receptor. Biochem Biophys Res Commun 200 (1994) 1214-1220
17. Chen A.S., Marsh D.J., Trumbauer M.E., Frazier E.G., Guan X.M., Yu H., et al. Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat Genet 26 (2000) 97-102
18. Butler A.A., Kesterson R.A., Khong K., Cullen M.J., Pelleymounter M.A., Dekoning J., et al. A unique metabolic syndrome causes obesity in the melanocortin-3 receptor-deficient mouse. Endocrinology 141 (2000) 3518-3521
19. Huszar D., Lynch C.A., Fairchild-Huntress V., Dunmore J.H., Fang Q., Berkemeier L.R., et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 88 (1997) 131-141
20. Chen W., Kelly M.A., Opitz-Araya X., Thomas R.E., Low M.J., and Cone R.D. Exocrine gland dysfunction in MC5-R-deficient mice: evidence for coordinated regulation of exocrine gland function by melanocortin peptides. Cell 91 (1997) 789-798
21. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., and Friedman J.M. Positional cloning of the mouse obese gene and its human homologue. Nature 372 (1994) 425-432
22. Cone R.D. Anatomy and regulation of the central melanocortin system. Nat Neurosci 8 (2005) 571-578
23. Spiegelman B.M., and Flier J.S. Obesity and the regulation of energy balance. Cell 104 (2001) 531-543
24. Brady L.S., Smith M.A., Gold P.W., and Herkenham M. Altered expression of hypothalamic neuropeptide mRNAs in food-restricted and food-deprived rats. Neuroendocrinology 52 (1990) 441-447
25. Bergendahl M., Wiemann J.N., Clifton D.K., Huhtaniemi I., and Steiner R.A. Short-term starvation decreases POMC mRNA but does not alter GnRH mRNA in the brain of adult male rats. Neuroendocrinology 56 (1992) 913-920
26. Mizuno T.M., Kleopoulos S.P., Bergen H.T., Roberts J.L., Priest C.A., and Mobbs C.V. Hypothalamic pro-opiomelanocortin mRNA is reduced by fasting and [corrected] in ob/ob and db/db mice, but is stimulated by leptin. Diabetes 47 (1998) 294-297
27. Hagan M.M., Rushing P.A., Schwartz M.W., Yagaloff K.A., Burn P., Woods S.C., et al. Role of the CNS melanocortin system in the response to overfeeding. J Neurosci 19 (1999) 2362-2367
28. Mizuno T.M., and Mobbs C.V. Hypothalamic agouti-related protein messenger ribonucleic acid is inhibited by leptin and stimulated by fasting. Endocrinology 140 (1999) 814-817
29. Chen H., Charlat O., Tartaglia L.A., Woolf E.A., Weng X., Ellis S.J., et al. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 84 (1996) 491-495
30. Yaswen L., Diehl N., Brennan M.B., and Hochgeschwender U. Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nat Med 5 (1999) 1066-1070
31. Naggert J.K., Fricker L.D., Varlamov O., Nishina P.M., Rouille Y., Steiner D.F., et al. Hyperproinsulinaemia in obese fat/fat mice associated with a carboxypeptidase E mutation which reduces enzyme activity. Nat Genet 10 (1995) 135-142
32. Montague C.T., Farooqi I.S., Whitehead J.P., Soos M.A., Rau H., Wareham N.J., et al. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 387 (1997) 903-908
33. Strobel A., Issad T., Camoin L., Ozata M., and Strosberg A.D. A leptin missense mutation associated with hypogonadism and morbid obesity. Nat Genet 18 (1998) 213-215
34. Clement K., Vaisse C., Lahlou N., Cabrol S., Pelloux V., Cassuto D., et al. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 392 (1998) 398-401
35. Krude H., Biebermann H., Luck W., Horn R., Brabant G., and Gruters A. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 19 (1998) 155-157
36. Jackson R.S., Creemers J.W., Ohagi S., Raffin-Sanson M.L., Sanders L., Montague C.T., et al. Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nat Genet 16 (1997) 303-306
37. Farooqi I.S., and O'Rahilly S. Mutations in ligands and receptors of the leptin-melanocortin pathway that lead to obesity. Nat Clin Pract Endocrinol Metab 4 (2008) 569-577
38. Farooqi I.S., Matarese G., Lord G.M., Keogh J.M., Lawrence E., Agwu C., et al. Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency. J Clin Invest 110 (2002) 1093-1103
39. Farooqi I.S., Wangensteen T., Collins S., Kimber W., Matarese G., Keogh J.M., et al. Clinical and molecular genetic spectrum of congenital deficiency of the leptin receptor. N Engl J Med 356 (2007) 237-247
40. Kimber W., Peelman F., Prieur X., Wangensteen T., O'Rahilly S., Tavernier J., et al. Functional characterization of naturally occurring pathogenic mutations in the human leptin receptor. Endocrinology 149 (2008) 6043-6052
41. Krude H., Biebermann H., Schnabel D., Tansek M.Z., Theunissen P., Mullis P.E., et al. Obesity due to proopiomelanocortin deficiency: three new cases and treatment trials with thyroid hormone and ACTH4-10. J Clin Endocrinol Metab 88 (2003) 4633-4640
42. Farooqi I.S., Drop S., Clements A., Keogh J.M., Biernacka J., Lowenbein S., et al. Heterozygosity for a POMC-null mutation and increased obesity risk in humans. Diabetes 55 (2006) 2549-2553
43. Lee Y.S., Challis B.G., Thompson D.A., Yeo G.S., Keogh J.M., Madonna M.E., et al. A POMC variant implicates β-melanocyte-stimulating hormone in the control of human energy balance. Cell Metab 3 (2006) 135-140
44. Biebermann H., Castaneda T.R., van Landeghem F., von Deimling A., Escher F., Brabant G., et al. A role for β-melanocyte-stimulating hormone in human body-weight regulation. Cell Metab 3 (2006) 141-146
45. Harrold J.A., and Williams G. Melanocortin-4 receptors, β-MSH and leptin: key elements in the satiety pathway. Peptides 27 (2006) 365-371
46. Jackson R.S., Creemers J.W., Farooqi I.S., Raffin-Sanson M.L., Varro A., Dockray G.J., et al. Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency. J Clin Invest 112 (2003) 1550-1560
47. Mountjoy K.G., Mortrud M.T., Low M.J., Simerly R.B., and Cone R.D. Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain. Mol Endocrinol 8 (1994) 1298-1308
48. Fan W., Boston B.A., Kesterson R.A., Hruby V.J., and Cone R.D. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 385 (1997) 165-168
49. Thiele T.E., van Dijk G., Yagaloff K.A., Fisher S.L., Schwartz M., Burn P., et al. Central infusion of melanocortin agonist MTII in rats: assessment of c-Fos expression and taste aversion. Am J Physiol 274 (1998) R248-R254
50. Grill H.J., Ginsberg A.B., Seeley R.J., and Kaplan J.M. Brainstem application of melanocortin receptor ligands produces long-lasting effects on feeding and body weight. J Neurosci 18 (1998) 10128-10135
51. Lu D., Willard D., Patel I.R., Kadwell S., Overton L., Kost T., et al. Agouti protein is an antagonist of the melanocyte-stimulating-hormone receptor. Nature 371 (1994) 799-802
52. Graham M., Shutter J.R., Sarmiento U., Sarosi I., and Stark K.L. Overexpression of Agrt leads to obesity in transgenic mice. Nat Genet 17 (1997) 273-274
53. Shutter J.R., Graham M., Kinsey A.C., Scully S., Luthy R., and Stark K.L. Hypothalamic expression of ART, a novel gene related to agouti, is up-regulated in obese and diabetic mutant mice. Genes Dev 11 (1997) 593-602
54. Marsh D.J., Hollopeter G., Huszar D., Laufer R., Yagaloff K.A., Fisher S.L., et al. Response of melanocortin-4 receptor-deficient mice to anorectic and orexigenic peptides. Nat Genet 21 (1999) 119-122
55. Chen A.S., Metzger J.M., Trumbauer M.E., Guan X.M., Yu H., Frazier E.G., et al. Role of the melanocortin-4 receptor in metabolic rate and food intake in mice. Transgenic Res 9 (2000) 145-154
56. Balthasar N., Dalgaard L.T., Lee C.E., Yu J., Funahashi H., Williams T., et al. Divergence of melanocortin pathways in the control of food intake and energy expenditure. Cell 123 (2005) 493-505
57. Williams D.L., Kaplan J.M., and Grill H.J. The role of the dorsal vagal complex and the vagus nerve in feeding effects of melanocortin-3/4 receptor stimulation. Endocrinology 141 (2000) 1332 1327
58. Vaisse C., Clement K., Guy-Grand B., and Froguel P. A frameshift mutation in human MC4R is associated with a dominant form of obesity. Nat Genet 20 (1998) 113-114
59. Yeo G.S., Farooqi I.S., Aminian S., Halsall D.J., Stanhope R.G., and O'Rahilly S. A frameshift mutation in MC4R associated with dominantly inherited human obesity. Nat Genet 20 (1998) 111-112
60. Gu W., Tu Z., Kleyn P.W., Kissebah A., Duprat L., Lee J., et al. Identification and functional analysis of novel human melanocortin-4 receptor variants. Diabetes 48 (1999) 635-639
61. Hinney A., Schmidt A., Nottebom K., Heibult O., Becker I., Ziegler A., et al. Several mutations in the melanocortin-4 receptor gene including a nonsense and a frameshift mutation associated with dominantly inherited obesity in humans. J Clin Endocrinol Metab 84 (1999) 1483-1486
62. Farooqi I.S., Yeo G.S., Keogh J.M., Aminian S., Jebb S.A., Butler G., et al. Dominant and recessive inheritance of morbid obesity associated with melanocortin 4 receptor deficiency. J Clin Invest 106 (2000) 271-279
63. Vaisse C., Clement K., Durand E., Hercberg S., Guy-Grand B., and Froguel P. Melanocortin-4 receptor mutations are a frequent and heterogeneous cause of morbid obesity. J Clin Invest 106 (2000) 253-262
64. Dubern B., Clement K., Pelloux V., Froguel P., Girardet J.P., Guy-Grand B., et al. Mutational analysis of melanocortin-4 receptor, agouti-related protein, and a-melanocyte-stimulating hormone genes in severely obese children. J Pediatr 139 (2001) 204-209
65. Mergen M., Mergen H., Ozata M., Oner R., and Oner C. A novel melanocortin 4 receptor (MC4R) gene mutation associated with morbid obesity. J Clin Endocrinol Metab 86 (2001) 3448-3451
66. Kobayashi H., Ogawa Y., Shintani M., Ebihara K., Shimodahira M., Iwakura T., et al. A novel homozygous missense mutation of melanocortin-4 receptor (MC4R) in a Japanese woman with severe obesity. Diabetes 51 (2002) 243-246
67. Miraglia Del Giudice E., Cirillo G., Nigro V., Santoro N., D'Urso L., Raimondo P., et al. Low frequency of melanocortin-4 receptor (MC4R) mutations in a Mediterranean population with early-onset obesity. Int J Obes Relat Metab Disord 26 (2002) 647-651
68. Jacobson P., Ukkola O., Rankinen T., Snyder E.E., Leon A.S., Rao D.C., et al. Melanocortin 4 receptor sequence variations are seldom a cause of human obesity: the Swedish Obese Subjects, the HERITAGE Family Study, and a Memphis cohort. J Clin Endocrinol Metab 87 (2002) 4442-4446
69. Marti A., Corbalan M.S., Forga L., Martinez J.A., Hinney A., and Hebebrand J. A novel nonsense mutation in the melanocortin-4 receptor associated with obesity in a Spanish population. Int J Obes Relat Metab Disord 27 (2003) 385-388
70. Lubrano-Berthelier C., Durand E., Dubern B., Shapiro A., Dazin P., Weill J., et al. Intracellular retention is a common characteristic of childhood obesity-associated MC4R mutations. Hum Mol Genet 12 (2003) 145-153
71. Farooqi I.S., Keogh J.M., Yeo G.S., Lank E.J., Cheetham T., and O'Rahilly S. Clinical spectrum of obesity and mutations in the melanocortin 4 receptor gene. N Engl J Med 348 (2003) 1085-1095
72. Yeo G.S., Lank E.J., Farooqi I.S., Keogh J., Challis B.G., and O'Rahilly S. Mutations in the human melanocortin-4 receptor gene associated with severe familial obesity disrupts receptor function through multiple molecular mechanisms. Hum Mol Genet 12 (2003) 561-574
73. Hinney A., Hohmann S., Geller F., Vogel C., Hess C., Wermter A.K., et al. Melanocortin-4 receptor gene: case-control study and transmission disequilibrium test confirm that functionally relevant mutations are compatible with a major gene effect for extreme obesity. J Clin Endocrinol Metab 88 (2003) 4258-4267
74. Tarnow P., Schoneberg T., Krude H., Gruters A., and Biebermann H. Mutationally induced disulfide bond formation within the third extracellular loop causes melanocortin 4 receptor inactivation in patients with obesity. J Biol Chem 278 (2003) 48666-48673
75. Donohoue P.A., Tao Y.X., Collins M., Yeo G.S.H., O'Rahilly S., and Segaloff D.L. Deletion of codons 88-92 of the melanocortin-4 receptor gene: a novel deleterious mutation in an obese female. J Clin Endocrinol Metab 88 (2003) 5841-5845
76. Biebermann H., Krude H., Elsner A., Chubanov V., Gudermann T., and Gruters A. Autosomal-dominant mode of inheritance of a melanocortin-4 receptor mutation in a patient with severe early-onset obesity is due to a dominant-negative effect caused by receptor dimerization. Diabetes 52 (2003) 2984-2988
77. Santini F., Maffei M., Ceccarini G., Pelosini C., Scartabelli G., Rosellini V., et al. Genetic screening for melanocortin-4 receptor mutations in a cohort of Italian obese patients: description and functional characterization of a novel mutation. J Clin Endocrinol Metab 89 (2004) 904-908
78. Valli-Jaakola K., Lipsanen-Nyman M., Oksanen L., Hollenberg A.N., Kontula K., Bjorbaek C., et al. Identification and characterization of melanocortin-4 receptor gene mutations in morbidly obese Finnish children and adults. J Clin Endocrinol Metab 89 (2004) 940-945
79. Lubrano-Berthelier C., Le Stunff C., Bougneres P., and Vaisse C. A homozygous null mutation delineates the role of the melanocortin-4 receptor in humans. J Clin Endocrinol Metab 89 (2004) 2028-2032
80. Ma L., Tataranni P.A., Bogardus C., and Baier L.J. Melanocortin 4 receptor gene variation is associated with severe obesity in Pima Indians. Diabetes 53 (2004) 2696-2699
81. Larsen L.H., Echwald S.M., Sorensen T.I., Andersen T., Wulff B.S., and Pedersen O. Prevalence of mutations and functional analyses of melanocortin 4 receptor variants identified among 750 men with juvenile-onset obesity. J Clin Endocrinol Metab 90 (2005) 219-224
82. Buono P., Pasanisi F., Nardelli C., Ieno L., Capone S., Liguori R., et al. Six novel mutations in the proopiomelanocortin and melanocortin receptor 4 genes in severely obese adults living in southern Italy. Clin Chem 51 (2005) 1358-1364
83. Shao X.Y., Jia W.P., Cai S.B., Fang Q.C., Zhang R., Lu J.X., et al. Cloning and functional analysis of melanocortin 4 receptor mutation gene F261S. Zhonghua Yi Xue Za Zhi 85 (2005) 366-369
84. Lubrano-Berthelier C., Dubern B., Lacorte J.M., Picard F., Shapiro A., Zhang S., et al. Melanocortin 4 receptor mutations in a large cohort of severely obese adults: prevalence, functional classification, genotype-phenotype relationship, and lack of association with binge eating. J Clin Endocrinol Metab 91 (2006) 1811-1818
85. Hinney A., Bettecken T., Tarnow P., Brumm H., Reichwald K., Lichtner P., et al. Prevalence, spectrum, and functional characterization of melanocortin-4 receptor gene mutations in a representative population-based sample and obese adults from Germany. J Clin Endocrinol Metab 91 (2006) 1761-1769
86. Rong R., Tao Y.X., Cheung B.M., Xu A., Cheung G.C., and Lam K.S. Identification and functional characterization of three novel human melanocortin-4 receptor gene variants in an obese Chinese population. Clin Endocrinol 65 (2006) 198-205
87. Wang C.L., Liang L., Wang H.J., Fu J.F., Hebebrand J., and Hinney A. Several mutations in the melanocortin 4 receptor gene are associated with obesity in Chinese children and adolescents. J Endocrinol Invest 29 (2006) 894-898
88. Alharbi K.K., Spanakis E., Tan K., Smith M.J., Aldahmesh M.A., O'Dell S.D., et al. Prevalence and functionality of paucimorphic and private MC4R mutations in a large, unselected European British population, scanned by meltMADGE. Hum Mutat 28 (2007) 294-302
89. Ahituv N., Kavaslar N., Schackwitz W., Ustaszewska A., Martin J., Hebert S., et al. Medical sequencing at the extremes of human body mass. Am J Hum Genet 80 (2007) 779-791
90. Ochoa M.C., Azcona C., Biebermann H., Brumm H., Razquin C., Wermter A.K., et al. A novel mutation Thr162Arg of the melanocortin 4 receptor gene in a Spanish children and adolescent population. Clin Endocrinol (Oxf) 66 (2007) 652-658
91. Rettenbacher E., Tarnow P., Brumm H., Prayer D., Wermter A.K., Hebebrand J., et al. A novel non-synonymous mutation in the melanocortin-4 receptor gene (MC4R) in a 2-year-old Austrian girl with extreme obesity. Exp Clin Endocrinol Diabetes 115 (2007) 7-12
92. Reinehr T., Hinney A., de Sousa G., Austrup F., Hebebrand J., and Andler W. Definable somatic disorders in overweight children and adolescents. J Pediatr 150 (2007) 618-622 e611-5
93. Hainerova I., Larsen L.H., Holst B., Finkova M., Hainer V., Lebl J., et al. Melanocortin 4 receptor mutations in obese Czech children: studies of prevalence, phenotype development, weight reduction response, and functional analysis. J Clin Endocrinol Metab 92 (2007) 3689-3696
94. Lee Y.S., Poh L.K., Kek B.L., and Loke K.Y. Novel melanocortin 4 receptor gene mutations in severely obese children. Clin Endocrinol (Oxf) 68 (2008) 529-535
95. Stutzmann F., Tan K., Vatin V., Dina C., Jouret B., Tichet J., et al. Prevalence of melanocortin-4 receptor deficiency in Europeans and their age-dependent penetrance in multigenerational pedigrees. Diabetes 57 (2008) 2511-2518
96. Krakoff J., Ma L., Kobes S., Knowler W.C., Hanson R.L., Bogardus C., et al. Lower metabolic rate in individuals heterozygous for either a frameshift or a functional missense MC4R variant. Diabetes 57 (2008) 3267-3272
97. Tan K., Pogozheva I.D., Yeo G.S., Hadaschik D., Keogh J.M., Haskell-Leuvano C., et al. Functional characterization and structural modeling of obesity associated mutations in the melanocortin 4 receptor. Endocrinology 150 (2009) 114-125
98. Roth C.L., Ludwig M., Woelfle J., Fan Z.C., Brumm H., Biebermann H., et al. A novel melanocortin-4 receptor gene mutation in a female patient with severe childhood obesity. Endocrine (2009) DOI: 10.1007/s12020-009-9156-4
99. Wangensteen T., Pollestad Kolsgaard M.L., Mattingsdal M., Joner G., Tonstad S., Undlien D., et al. Mutations in the melanocortin 4 receptor (MC4R) gene in obese patients in Norway. Exp Clin Endocrinol Diabetes (2009) DOI: 10.1055/s-0028-1102942
100. Lubrano-Berthelier C., Cavazos M., Le Stunff C., Haas K., Shapiro A., Zhang S., et al. The human MC4R promoter: characterization and role in obesity. Diabetes 52 (2003) 2996-3000
101. Valli-Jaakola K., Palvimo J.J., Lipsanen-Nyman M., Salomaa V., Peltonen L., Kontula K., et al. A two-base deletion-439delGC in the melanocortin-4 receptor promoter associated with early-onset obesity. Horm Res 66 (2006) 61-69
102. Loos R.J., Rankinen T., Tremblay A., Perusse L., Chagnon Y., and Bouchard C. Melanocortin-4 receptor gene and physical activity in the Quebec Family Study. Int J Obes Relat Metab Disord 29 (2005) 420-428
103. Chambers J.C., Elliott P., Zabaneh D., Zhang W., Li Y., Froguel P., et al. Common genetic variation near MC4R is associated with waist circumference and insulin resistance. Nat Genet 40 (2008) 716-718
104. Loos R.J., Lindgren C.M., Li S., Wheeler E., Zhao J.H., Prokopenko I., et al. Common variants near MC4R are associated with fat mass, weight and risk of obesity. Nat Genet 40 (2008) 768-775
105. Qi L., Kraft P., Hunter D.J., and Hu F.B. The common obesity variant near MC4R gene is associated with higher intakes of total energy and dietary fat, weight change and diabetes risk in women. Hum Mol Genet 17 (2008) 3502-3508
106. Calton M.A., Ersoy B.A., Zhang S., Kane J.P., Malloy M.J., Pullinger C.R., et al. Association of functionally significant Melanocortin-4 but not Melanocortin-3 receptor mutations with severe adult obesity in a large North American case-control study. Hum Mol Genet 18 (2009) 1140-1147
107. Ohshiro Y., Sanke T., Ueda K., Shimajiri Y., Nakagawa T., Tsunoda K., et al. Molecular scanning for mutations in the melanocortin-4 receptor gene in obese/diabetic Japanese. Ann Hum Genet 63 (1999) 483-487
108. Fang Q.C., Jia W.P., Cai S.B., Shao X.Y., Zhang R., Wang C.R., et al. Intracellular retention of human melanocortin-4 receptor: a molecular mechanism underlying early-onset obesity in F261S pedigree of Chinese. Biomed Environ Sci 21 (2008) 280-285
109. Dempfle A., Hinney A., Heinzel-Gutenbrunner M., Raab M., Geller F., Gudermann T., et al. Large quantitative effect of melanocortin-4 receptor gene mutations on body mass index. J Med Genet 41 (2004) 795-800
110. Ste Marie L., Miura G.I., Marsh D.J., Yagaloff K., and Palmiter R.D. A metabolic defect promotes obesity in mice lacking melanocortin-4 receptors. Proc Natl Acad Sci USA 97 (2000) 12339-12344
111. Greenfield J.R., Miller J.W., Keogh J.M., Henning E., Satterwhite J.H., Cameron G.S., et al. Modulation of blood pressure by central melanocortinergic pathways. N Engl J Med 360 (2009) 44-52
112. Rosmond R., Chagnon M., Bouchard C., and Bjorntorp P. A missense mutation in the human melanocortin-4 receptor gene in relation to abdominal obesity and salivary cortisol. Diabetologia 44 (2001) 1335-1338
113. Geller F., Reichwald K., Dempfle A., Illig T., Vollmert C., Herpertz S., et al. Melanocortin-4 receptor gene variant I103 is negatively associated with obesity. Am J Hum Genet 74 (2004) 572-581
114. Young E.H., Wareham N.J., Farooqi S., Hinney A., Hebebrand J., Scherag A., et al. The V103I polymorphism of the MC4R gene and obesity: population based studies and meta-analysis of 29 563 individuals. Int J Obes (Lond) 31 (2007) 1437-1441
115. Ho G., and MacKenzie R.G. Functional characterization of mutations in melanocortin-4 receptor associated with human obesity. J Biol Chem 274 (1999) 35816-35822
116. Xiang Z., Litherland S.A., Sorensen N.B., Proneth B., Wood M.S., Shaw A.M., et al. Pharmacological characterization of 40 human melanocortin-4 receptor polymorphisms with the endogenous proopiomelanocortin-derived agonists and the agouti-related protein (AGRP) antagonist. Biochemistry 45 (2006) 7277-7288
117. Stutzmann F., Vatin V., Cauchi S., Morandi A., Jouret B., Landt O., et al. Non-synonymous polymorphisms in melanocortin-4 receptor protect against obesity: the two facets of a Janus obesity gene. Hum Mol Genet 16 (2007) 1837-1844
118. Sina M., Hinney A., Ziegler A., Neupert T., Mayer H., Siegfried W., et al. Phenotypes in three pedigrees with autosomal dominant obesity caused by haploinsufficiency mutations in the melanocortin-4 receptor gene. Am J Hum Genet 65 (1999) 1501-1507
119. Hebebrand J., Fichter M., Gerber G., Gorg T., Hermann H., Geller F., et al. Genetic predisposition to obesity in bulimia nervosa: a mutation screen of the melanocortin-4 receptor gene. Mol Psychiatry 7 (2002) 647-651
120. Branson R., Potoczna N., Kral J.G., Lentes K.U., Hoehe M.R., and Horber F.F. Binge eating as a major phenotype of melanocortin 4 receptor gene mutations. N Engl J Med 348 (2003) 1096-1103
121. Tao Y.X., and Segaloff D.L. Functional analyses of melanocortin-4 receptor mutations identified from patients with binge eating disorder and nonobese or obese subjects. J Clin Endocrinol Metab 90 (2005) 5632-5638
122. Hebebrand J., Geller F., Dempfle A., Heinzel-Gutenbrunner M., Raab M., Gerber G., et al. Binge-eating episodes are not characteristic of carriers of melanocortin-4 receptor gene mutations. Mol Psychiatry 9 (2004) 796-800
123. Farooqi S., Yeo G.S., and O'Rahilly S. Binge eating as a phenotype of melanocortin 4 receptor gene mutations. N Engl J Med 349 (2003) 606-609 author reply 606-9
124. Tao Y.X., Johnson N.B., and Segaloff D.L. Constitutive and agonist-dependent self-association of the cell surface human lutropin receptor. J Biol Chem 279 (2004) 5904-5914
125. Tao Y.X., and Segaloff D.L. Functional characterization of melanocortin-4 receptor mutations associated with childhood obesity. Endocrinology 144 (2003) 4544-4551
126. Sung C.H., Schneider B.G., Agarwal N., Papermaster D.S., and Nathans J. Functional heterogeneity of mutant rhodopsins responsible for autosomal dominant retinitis pigmentosa. Proc Natl Acad Sci USA 88 (1991) 8840-8844
127. Sung C.H., Davenport C.M., and Nathans J. Rhodopsin mutations responsible for autosomal dominant retinitis pigmentosa. Clustering of functional classes along the polypeptide chain. J Biol Chem 268 (1993) 26645-26649
128. Morello J.P., and Bichet D.G. Nephrogenic diabetes insipidus. Annu Rev Physiol 63 (2001) 607-630
129. Tanaka H., Moroi K., Iwai J., Takahashi H., Ohnuma N., Hori S., et al. Novel mutations of the endothelin B receptor gene in patients with Hirschsprung's disease and their characterization. J Biol Chem 273 (1998) 11378-11383
130. o-sensing receptor. J Biol Chem 271 (1996) 19537-19545
131. Leanos-Miranda A., Janovick J.A., and Conn P.M. Receptor-misrouting: an unexpectedly prevalent and rescuable etiology in gonadotropin-releasing hormone receptor-mediated hypogonadotropic hypogonadism. J Clin Endocrinol Metab 87 (2002) 4825-4828
132. Themmen A.P.N., and Huhtaniemi I.T. Mutations of gonadotropins and gonadotropin receptors: elucidating the physiology and pathophysiology of pituitary-gonadal function. Endocr Rev 21 (2000) 551-583
133. Tao Y.X. Inactivating mutations of G protein-coupled receptors and diseases: Structure-function insights and therapeutic implications. Pharmacol Ther 111 (2006) 949-973
134. Tarnow P., Rediger A., Brumm H., Ambrugger P., Rettenbacher E., Widhalm K., et al. A heterozygous mutation in the third transmembrane domain causes a dominant-negative effect on signaling capability of the MC4R. Obes Facts 1 (2008) 155-162
135. Colley N.J., Cassill J.A., Baker E.K., and Zuker C.S. Defective intracellular transport is the molecular basis of rhodopsin-dependent dominant retinal degeneration. Proc Natl Acad Sci USA 92 (1995) 3070-3074
136. Benkirane M., Jin D.Y., Chun R.F., Koup R.A., and Jeang K.T. Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5Δ32. J Biol Chem 272 (1997) 30603-30606
137. Overton M.C., and Blumer K.J. G-protein-coupled receptors function as oligomers in vivo. Current Biology 10 (2000) 341-344
138. Bulenger S., Marullo S., and Bouvier M. Emerging role of homo- and heterodimerization in G-protein-coupled receptor biosynthesis and maturation. Trends Pharmacol Sci 26 (2005) 131-137
139. Mandrika I., Petrovska R., and Wikberg J. Melanocortin receptors form constitutive homo- and heterodimers. Biochem Biophys Res Commun 326 (2005) 349-354
140. Hobbs H.H., Russell D.W., Brown M.S., and Goldstein J.L. The LDL receptor locus in familial hypercholesterolemia: mutational analysis of a membrane protein. Annu Rev Genet 24 (1990) 133-170
141. Welsh M.J., and Smith A.E. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 73 (1993) 1251-1254
142. Fan Z.C., and Tao Y.X. Functional characterization and pharmacological rescue of melanocortin-4 receptor mutations identified from obese patients. J Cell Mol Med (2009) DOI: 10.1111/j.1582-4934.2009.00726.x
143. Nijenhuis W.A., Garner K.M., VanRozen R.J., and Adan R.A. Poor cell surface expression of human melanocortin-4 receptor mutations associated with obesity. J Biol Chem 278 (2003) 22939-22945
144. VanLeeuwen D., Steffey M.E., Donahue C., Ho G., and MacKenzie R.G. Cell surface expression of the melanocortin-4 receptor is dependent on a C-terminal di-isoleucine sequence at codons 316/317. J Biol Chem 278 (2003) 15935-15940
145. Srinivasan S., Lubrano-Berthelier C., Govaerts C., Picard F., Santiago P., Conklin B.R., et al. Constitutive activity of the melanocortin-4 receptor is maintained by its N-terminal domain and plays a role in energy homeostasis in humans. J Clin Invest 114 (2004) 1158-1164
146. Mackenzie R.G. Obesity-associated mutations in the human melanocortin-4 receptor gene. Peptides 27 (2006) 395-403
147. Govaerts C., Srinivasan S., Shapiro A., Zhang S., Picard F., Clement K., et al. Obesity-associated mutations in the melanocortin 4 receptor provide novel insights into its function. Peptides 26 (2005) 1909-1919
148. Tao Y.X. Molecular mechanisms of the neural melanocortin receptor dysfunction in severe early onset obesity. Mol Cell Endocrinol 239 (2005) 1-14
149. Barak L.S., Oakley R.H., Laporte S.A., and Caron M.G. Constitutive arrestin-mediated desensitization of a human vasopressin receptor mutant associated with nephrogenic diabetes insipidus. Proc Natl Acad Sci USA 98 (2001) 93-98
150. Fan Z.C., Sartin J.L., and Tao Y.X. Pharmacological analyses of two naturally occurring porcine melanocortin-4 receptor mutations in domestic pigs. Domest Anim Endocrinol 34 (2008) 383-390
151. Dong C., Filipeanu C.M., Duvernay M.T., and Wu G. Regulation of G protein-coupled receptor export trafficking. Biochim Biophys Acta 1768 (2007) 853-870
152. Schulein R., Hermosilla R., Oksche A., Dehe M., Wiesner B., Krause G., et al. A dileucine sequence and an upstream glutamate residue in the intracellular carboxyl terminus of the vasopressin V2 receptor are essential for cell surface transport in COS.M6 cells. Mol Pharmacol 54 (1998) 525-535
153. Nakamura K., and Ascoli M. A dileucine-based motif in the C-terminal tail of the lutropin/choriogonadotropin receptor inhibits endocytosis of the agonist-receptor complex. Mol Pharmacol 56 (1999) 728-736
154. Thielen A., Oueslati M., Hermosilla R., Krause G., Oksche A., Rosenthal W., et al. The hydrophobic amino acid residues in the membrane-proximal C tail of the G protein-coupled vasopressin V2 receptor are necessary for transport-competent receptor folding. FEBS Lett 579 (2005) 5227-5235
155. Yang Y.K., Fong T.M., Dickinson C.J., Mao C., Li J.Y., Tota M.R., et al. Molecular determinants of ligand binding to the human melanocortin-4 receptor. Biochemistry 39 (2000) 14900-14911
156. Haskell-Luevano C., Cone R.D., Monck E.K., and Wan Y.P. Structure activity studies of the melanocortin-4 receptor by in vitro mutagenesis: identification of agouti-related protein (AGRP), melanocortin agonist and synthetic peptide antagonist interaction determinants. Biochemistry 40 (2001) 6164-6179
157. 2-adrenergic receptor-G-protein interactions. J Biol Chem 269 (1994) 29557-29564
158. Tao Q., and Abood M.E. Mutation of a highly conserved aspartate residue in the second transmembrane domain of the cannabinoid receptors, CB1 and CB2, disrupts G-protein coupling. J Pharmacol Exp Ther 285 (1998) 651-658
159. Roche J.P., Bounds S., Brown S., and Mackie K. A mutation in the second transmembrane region of the CB1 receptor selectively disrupts G protein signaling and prevents receptor internalization. Mol Pharmacol 56 (1999) 611-618
160. Kim K.S., Larsen N., Short T., Plastow G., and Rothschild M.F. A missense variant of the porcine melanocortin-4 receptor (MC4R) gene is associated with fatness, growth, and feed intake traits. Mamm Genome 11 (2000) 131-135
161. Kim K.S., Reecy J.M., Hsu W.H., Anderson L.L., and Rothschild M.F. Functional and phylogenetic analyses of a melanocortin-4 receptor mutation in domestic pigs. Domest Anim Endocrinol 26 (2004) 75-86
162. Patten C.S., Daniels D., Suzuki A., Fluharty S.J., and Yee D.K. Structural and signaling requirements of the human melanocortin 4 receptor for MAP kinase activation. Regul Pept 142 (2007) 111-122
163. Liu G.L., Jiang S.W., Xiong Y.Z., Zheng R., and Qu Y.C. Molecular screening of MC4R gene and association with fat traits in pig resource family. Yi Chuan Xue Bao 29 (2002) 497-501
164. Hernandez-Sanchez J., Visscher P., Plastow G., and Haley C. Candidate gene analysis for quantitative traits using the transmission disequilibrium test: the example of the melanocortin 4-receptor in pigs. Genetics 164 (2003) 637-644
165. Houston R.D., Cameron N.D., and Rance K.A. A melanocortin-4 receptor (MC4R) polymorphism is associated with performance traits in divergently selected Large White pig populations. Anim Genet 35 (2004) 386-390
166. Meidtner K., Wermter A.K., Hinney A., Remschmidt H., Hebebrand J., and Fries R. Association of the melanocortin 4 receptor with feed intake and daily gain in F2 Mangalitsa x Pietrain pigs. Anim Genet 37 (2006) 245-247
167. Park H.B., Carlborg O., Marklund S., and Andersson L. Melanocortin-4 receptor (MC4R) genotypes have no major effect on fatness in a Large White x Wild Boar intercross. Anim Genet 33 (2002) 155-157
168. Andersson L. Melanocortin receptor variants with phenotypic effects in horse, pig, and chicken. Ann NY Acad Sci 994 (2003) 313-318
169. Stachowiak M., Szydlowski M., Obarzanek-Fojt M., and Switonski M. An effect of a missense mutation in the porcine melanocortin-4 receptor (MC4R) gene on production traits in Polish pig breeds is doubtful. Anim Genet 37 (2006) 55-57
170. Xiang Z., Pogozheva I.D., Sorenson N.B., Wilczynski A.M., Holder J.R., Litherland S.A., et al. Peptide and small molecules rescue the functional activity and agonist potency of dysfunctional human melanocortin-4 receptor polymorphisms. Biochemistry 46 (2007) 8273-8287
171. Morello J.P., Salahpour A., Laperriere A., Bernier V., Arthus M.F., Lonergan M., et al. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J Clin Invest 105 (2000) 887-895
172. Janovick J.A., Maya-Nunez G., and Conn P.M. Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel disease etiology and therapeutic target. J Clin Endocrinol Metab 87 (2002) 3255-3262
173. Janovick J.A., Goulet M., Bush E., Greer J., Wettlaufer D.G., and Conn P.M. Structure-activity relations of successful pharmacologic chaperones for rescue of naturally occurring and manufactured mutants of the gonadotropin-releasing hormone receptor. J Pharmacol Exp Ther 305 (2003) 608-614
174. Noorwez S.M., Kuksa V., Imanishi Y., Zhu L., Filipek S., Palczewski K., et al. Pharmacological chaperone-mediated in vivo folding and stabilization of the P23H-opsin mutant associated with autosomal dominant retinitis pigmentosa. J Biol Chem 278 (2003) 14442-14450
175. Noorwez S.M., Malhotra R., McDowell J.H., Smith K.A., Krebs M.P., and Kaushal S. Retinoids assist the cellular folding of the autosomal dominant retinitis pigmentosa opsin mutant P23H. J Biol Chem 279 (2004) 16278-16284
176. Petaja-Repo U.E., Hogue M., Bhalla S., Laperriere A., Morello J.P., and Bouvier M. Ligands act as pharmacological chaperones and increase the efficiency of δ opioid receptor maturation. EMBO J 21 (2002) 1628-1637
177. Chaipatikul V., Erickson-Herbrandson L.J., Loh H.H., and Law P.Y. Rescuing the traffic-deficient mutants of rat μ-opioid receptors with hydrophobic ligands. Mol Pharmacol 64 (2003) 32-41
178. Fan J., Perry S.J., Gao Y., Schwarz D.A., and Maki R.A. A point mutation in the human melanin concentrating hormone receptor 1 reveals an important domain for cellular trafficking. Mol Endocrinol 19 (2005) 2579-2590
179. Van Craenenbroeck K., Clark S.D., Cox M.J., Oak J.N., Liu F., and Van Tol H.H. Folding efficiency is rate-limiting in dopamine D4 receptor biogenesis. J Biol Chem 280 (2005) 19350-19357
180. Robert J., Auzan C., Ventura M.A., and Clauser E. Mechanisms of cell-surface rerouting of an endoplasmic reticulum-retained mutant of the vasopressin V1b/V3 receptor by a pharmacological chaperone. J Biol Chem 280 (2005) 42198-42206
181. Hawtin S.R. Pharmacological chaperone activity of SR49059 to functionally recover misfolded mutations of the vasopressin V1a receptor. J Biol Chem 281 (2006) 14604-14614
182. Fortin J.P., Dziadulewicz E.K., Gera L., and Marceau F. A nonpeptide antagonist reveals a highly glycosylated state of the rabbit kinin B1 receptor. Mol Pharmacol 69 (2006) 1146-1157
183. Bernier V., Morello J.P., Zarruk A., Debrand N., Salahpour A., Lonergan M., et al. Pharmacologic chaperones as a potential treatment for X-linked nephrogenic diabetes insipidus. J Am Soc Nephrol 17 (2006) 232-243
184. Vos T.J., Caracoti A., Che J.L., Dai M., Farrer C.A., Forsyth N.E., et al. Identification of 2-[2-[2-(5-bromo-2-methoxyphenyl)-ethyl]-3-fluorophenyl]-4,5-dihydro-1H-imidazole (ML00253764), a small molecule melanocortin 4 receptor antagonist that effectively reduces tumor-induced weight loss in a mouse model. J Med Chem 47 (2004) 1602-1604
185. Nicholson J.R., Kohler G., Schaerer F., Senn C., Weyermann P., and Hofbauer K.G. Peripheral administration of a melanocortin 4-receptor inverse agonist prevents loss of lean body mass in tumor-bearing mice. J Pharmacol Exp Ther 317 (2006) 771-777
186. Rankinen T., Zuberi A., Chagnon Y.C., Weisnagel S.J., Argyropoulos G., Walts B., et al. The human obesity gene map: the 2005 update. Obesity (Silver Spring) 14 (2006) 529-644